NEO-DARK
| Patologia: | Carcinoma colon-rettale |
| Area Tematica: | Oncologia |
| Data di Inizio Progetto: | 01.05.2026 |
| Data di Fine Progetto: | 30.04.2028 |
| Finanziamento: | € 500.000,00 |
| Partenariato | ASST Grande Ospedale Metropolitano Niguarda Istituto Nazionale di Genetica Molecolare |
More intensive treatments of EO-CRC patients do not translate into survival advantages. Thus, more tailored treatments are warranted. Retrotransposable elements (RE) may generate neo-antigens potentially triggering immune response against tumors. We will assess whether RE-derived neoantigens are overexpressed in EO-CRC potentially representing a novel target for cancer immunotherapy.